These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29423972)

  • 1. The art and science of choosing efficacy endpoints for rare disease clinical trials.
    Cox GF
    Am J Med Genet A; 2018 Apr; 176(4):759-772. PubMed ID: 29423972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
    Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
    PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force.
    Walton MK; Powers JH; Hobart J; Patrick D; Marquis P; Vamvakas S; Isaac M; Molsen E; Cano S; Burke LB;
    Value Health; 2015 Sep; 18(6):741-52. PubMed ID: 26409600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
    Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.
    Raghu G; Collard HR; Anstrom KJ; Flaherty KR; Fleming TR; King TE; Martinez FJ; Brown KK
    Am J Respir Crit Care Med; 2012 May; 185(10):1044-8. PubMed ID: 22505745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials.
    Hindiyeh NA; Kellerman DJ; Schmidt PC
    Headache; 2019 May; 59(5):819-824. PubMed ID: 30953576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers and surrogate endpoints in clinical trials.
    Fleming TR; Powers JH
    Stat Med; 2012 Nov; 31(25):2973-84. PubMed ID: 22711298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Composite endpoints, including patient reported outcomes, in rare diseases.
    Verbeeck J; Dirani M; Bauer JW; Hilgers RD; Molenberghs G; Nabbout R
    Orphanet J Rare Dis; 2023 Sep; 18(1):262. PubMed ID: 37658423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endpoints in the design of clinical trials for primary sclerosing cholangitis.
    Ponsioen CY
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1410-1414. PubMed ID: 28847513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints.
    Kakkis ED; O'Donovan M; Cox G; Hayes M; Goodsaid F; Tandon PK; Furlong P; Boynton S; Bozic M; Orfali M; Thornton M
    Orphanet J Rare Dis; 2015 Feb; 10():16. PubMed ID: 25757705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.
    Liberti L; Stolk P; McAuslane JN; Schellens J; Breckenridge AM; Leufkens H
    Oncologist; 2015 Jun; 20(6):683-91. PubMed ID: 25948678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial.
    Xiong C; Yu K; Gao F; Yan Y; Zhang Z
    Clin Trials; 2005; 2(5):387-93. PubMed ID: 16317808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of early efficacy endpoints for proof-of-concept trials.
    Chen C; Sun L; Li CL
    J Biopharm Stat; 2013 Mar; 23(2):413-24. PubMed ID: 23437947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
    Kesselheim AS; Myers JA; Avorn J
    JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.
    Ponsioen CY; Chapman RW; Chazouillères O; Hirschfield GM; Karlsen TH; Lohse AW; Pinzani M; Schrumpf E; Trauner M; Gores GJ
    Hepatology; 2016 Apr; 63(4):1357-67. PubMed ID: 26418478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges of developing and conducting clinical trials in rare disorders.
    Kempf L; Goldsmith JC; Temple R
    Am J Med Genet A; 2018 Apr; 176(4):773-783. PubMed ID: 28815894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration.
    Schaal KB; Rosenfeld PJ; Gregori G; Yehoshua Z; Feuer WJ
    Ophthalmology; 2016 May; 123(5):1060-79. PubMed ID: 26952592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.
    Wallach JD; Ciani O; Pease AM; Gonsalves GS; Krumholz HM; Taylor RS; Ross JS
    BMC Med; 2018 Mar; 16(1):45. PubMed ID: 29562926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.
    Wittkop L; Smith C; Fox Z; Sabin C; Richert L; Aboulker JP; Phillips A; Chêne G; Babiker A; Thiébaut R;
    Clin Trials; 2010 Feb; 7(1):19-35. PubMed ID: 20156955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of endpoint characteristics in periodontal clinical trials published 1988-1992, and implications for future studies.
    Hujoel PP; DeRouen TA
    J Clin Periodontol; 1995 May; 22(5):397-407. PubMed ID: 7601922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.